Expansion plans expected to drive EBITDA growth at Create

The opening of new clinics and increasing patient numbers will drive ‘strong and sustainable’ EBITDA over the next three years, fertility provider Create Health said as it announced a 16% rise in turnover for the year ended 31 March 2018.

The company, which operates four full clinics including IVF laboratories and three satellite locations, plans to roll out further sites as patient demand increases.

Turnover for the year to March 2018 came in at £16.4m against £13.7m the previous year. Cost of sales increased from £2.8m to £3.3m, leaving gross profit before administrative expenses of £13.1m. Operating profit was 21% ahead of 2017 at £1.7m.

‘The group is one of the largest providers of fertility treatment in the UK and employs the leading team of fertility specialists in the UK,’ said the company. ‘The group is largely insulated from the risk of government funding cuts to fertility treatments, through strong private patient income. The service consistently delivers excellent quality and safe treatment and has a strong reputation, which helps to limit risks to trading.’